25 September 2026 · Medical Device Network
FDA grants breakthrough designation to infant insulin dosing algorithm
Doctors & NHSeHealth & digital healthMedical businessesRegulation & claims
The US FDA has granted breakthrough device designation to Glytec’s proposed Glucommander Pediatrics insulin dosing recommendation algorithm. It is intended for hospitalised newborns and infants under two years old.
Why it matters
Software supporting insulin dosing in very young patients is relevant to clinical risk and medical device oversight. The reported milestone is breakthrough designation, not a statement of marketing approval.
Protect your practice
Summary for general information only — not legal, clinical or insurance advice.